台股 » 個股 » 訊聯 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

訊聯

(1784)
可現股當沖
  • 股價
    80.9
  • 漲跌
    ▲0.6
  • 漲幅
    +0.75%
  • 成交量
    476
  • 產業
    上櫃 生技醫療類股▲1.27%
  • 119人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
訊聯 (1784)籌碼相關-安泰-大發 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

安泰-大發 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/12/20179.0000.0079.1015440.18%
2024/12/18182.3000.0082.4015480.18%
2024/12/13189.9000.0087.2015870.17%
2024/12/0400.00199.10100.50-1550-0.18%
2024/12/0200.00196.0096.50-1523-0.19%
2024/11/2900.00197.5097.00-1519-0.19%
2024/11/2800.00190.7090.60-1512-0.20%
2024/11/25197.9000.0097.4015650.18%
2024/11/01191.2000.0091.2018240.12%
2024/10/1100.00393.6090.90-31,571-0.19%
2024/10/0900.00297.1096.10-21,585-0.13%
2024/10/0800.00198.4098.00-11,594-0.06%
2024/10/0700.00199.3099.40-11,642-0.06%
2024/08/211116.0000.00117.0012,9980.03%
2024/08/2000.001117.00116.00-12,973-0.03%
2024/08/1600.002112.50113.00-22,933-0.07%
2024/08/122115.7500.00112.0022,9620.07%
2024/08/0500.003102.1799.50-32,853-0.11%
2024/08/0200.001111.50110.50-12,818-0.04%
2024/07/2900.002114.00113.50-22,748-0.07%
2024/07/192150.0000.00145.5022,5720.08%
2024/07/0800.001145.50146.00-12,083-0.05%
2024/07/0400.001131.50135.50-12,027-0.05%
2024/07/032135.251136.00133.0012,0080.05%
2024/07/023133.0000.00140.0031,9350.16%
2024/07/011129.0000.00139.5011,7290.06%
2024/06/281122.5000.00127.0011,6230.06%
2024/06/25195.0000.0095.6011,3880.07%
2024/06/24195.0000.0094.2011,3710.07%
2024/06/18192.6000.0096.1011,2420.08%
2024/06/17294.00188.4091.5011,1950.08%
2024/06/1200.00883.0483.40-81,069-0.75%
2024/05/31881.8000.0082.4086901.16%
2024/05/3000.00178.0077.30-1607-0.16%
2024/05/20271.80172.5071.7014710.21%
2024/05/17170.5000.0069.9014540.22%
2024/05/0900.00165.2065.60-1404-0.25%
2024/04/26266.0000.0066.4023550.56%
2024/04/0100.00263.0063.00-2254-0.79%
2024/03/20266.0000.0066.0022510.80%
2024/03/1800.00162.5062.60-1231-0.43%
2024/03/0500.00363.0062.70-3226-1.33%
2024/02/1600.00260.0060.20-2200-1.00%
訊聯2024年外泌體與幹細胞趨勢論壇 聚焦羊水與臍帶血應用Anue鉅亨-1天前
訊聯H1外泌體業績年增1.8倍 旗下訊聯細胞智藥擬Q4登興櫃Anue鉅亨-2024/08/26
訊聯 相關文章
訊聯 相關影音